Parita Shah, in Copperas Cove, TX - Physical Therapist

Parita Shah, is a Physical Therapist physician based in Copperas Cove, Texas. Parita Shah is licensed to practice in California (license number 300395) and her current practice location is 810 Industrial Ave, Copperas Cove, Texas. She can be reached at her office (for appointments etc.) via phone at (254) 547-9552.

NPI number for Parita Shah is 1386125284 and her current mailing address is 600 N Pearl St Ste 1050, Dallas, Texas. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1386125284.

Contact Information

	Parita Shah,
	810 Industrial Ave, Copperas Cove, TX 76522-1722
	(254) 547-9552
	Not Available

Physician's Profile

Full Name	Parita Shah
Gender	Female
Speciality	Physical Therapist
Location	810 Industrial Ave, Copperas Cove, Texas
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1386125284
Provider Enumeration Date: 08/28/2018
Last Update Date: 07/07/2021

Medical Identifiers

Medical identifiers for Parita Shah such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1386125284	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208100000X	Physical Medicine & Rehabilitation	1280312 (Texas)	Secondary
225100000X	Physical Therapist	300395 (California)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Parita Shah is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Parita Shah, 600 N Pearl St Ste 1050, Dallas, TX 75201-7495 Ph: () -	Parita Shah, 810 Industrial Ave, Copperas Cove, TX 76522-1722 Ph: (254) 547-9552

News Archive

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors.

Fifi Delish, 50,000feet introduce ViviLeDish for young children

50,000feet, Inc. and Fifi Delish Holding, LLC announced the launch of ViviLeDish.com, an interactive platform designed to help young children develop healthy attitudes and habits about food, eating and exercise that will last a lifetime.

Anti-sense agents suppress SARS-CoV-2 virus

Researchers in the United States have conducted a study showing that anti-sense agents called peptide-conjugated morpholino oligomers (PPMOs) have the ability to specifically and potently suppress the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

Persistent infection in infant reveals mutation that helps bacteria tolerate antibiotic therapy

The quest to understand a prolonged infection in an infant being treated for leukemia has led to the St. Jude Children's Research Hospital discovery of a mutation that allows bacteria to tolerate normally effective antibiotic therapy. The report appears today in the scientific journal mBio.

Survivors of childhood leukemia and lymphoma are at greater risk of chronic fatigue: Study

Chronic fatigue, a persistent lack of energy that does not improve with rest, is at least three times more prevalent among adult survivors of acute lymphoblastic leukemia and lymphoma experienced during childhood or adolescence than in the general adult population, according to an article in Journal of Adolescent and Young Adult Oncology, a multidisciplinary peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

Parita Shah, - Physical Therapist in Copperas Cove, TX